TOKYO -- Japanese traditional drugmaker Tsumura & Co. will cultivate the Chinese market by tapping the broad customer base and professional network of local company Ping An Insurance Group, with which a tie-up was announced last month.
The two companies are expected to establish a joint venture, with Tsumura taking a majority stake. The new company will integrate all operations from procurement of ingredients to sales. The partners are also searching for land in candidate cities such as Shenzhen to build a research center. The facility will develop traditional medicine and quality control technology among other things. Construction could begin as early as 2018.
By continuing to browse this website, you accept cookies which are used for several reasons such as personalizing content/ads and analyzing how this website is used. Please review our
to learn how you can update your cookie settings.